Thrombotic microangiopathies.
Ruggenenti
P
P
Mario Negri Institute for Pharmacological Research, Ospedali Riuniti di Bergamo, Italy.
Remuzzi
G
G
D000328:Adult; D002648:Child; D016572:Cyclosporine / Q000009:adverse effects; D004730:Endothelium, Vascular / Q000473:pathology; D005260:Female; D020022:Genetic Predisposition to Disease; D006463:Hemolytic-Uremic Syndrome / Q000150:complications*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007239:Infections / Q000150:complications; D007668:Kidney / Q000473:pathology; D016030:Kidney Transplantation / Q000009:adverse effects; D008833:Microcirculation; D009369:Neoplasms / Q000150:complications; D010951:Plasma Exchange; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic; D011697:Purpura, Thrombotic Thrombocytopenic / Q000150:complications*; D013927:Thrombosis / Q000209:etiology / Q000503:physiopathology / Q000628:therapy
D007166:Immunosuppressive Agents; D010975:Platelet Aggregation Inhibitors; D016572:Cyclosporine